1. Home
  2. MVIS vs CGTX Comparison

MVIS vs CGTX Comparison

Compare MVIS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MicroVision Inc.

MVIS

MicroVision Inc.

HOLD

Current Price

$1.70

Market Cap

86.6M

Sector

Technology

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVIS
CGTX
Founded
1993
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.6M
79.6M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
MVIS
CGTX
Price
$1.70
$1.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$2.25
$3.33
AVG Volume (30 Days)
1.3M
342.4K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
23.91
62.79
EPS
N/A
N/A
Revenue
$664,000.00
N/A
Revenue This Year
$529.06
N/A
Revenue Next Year
$168.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.55
52 Week High
$4.90
$2.05

Technical Indicators

Market Signals
Indicator
MVIS
CGTX
Relative Strength Index (RSI) 49.54 54.78
Support Level $1.65 $1.03
Resistance Level $1.93 $1.18
Average True Range (ATR) 0.13 0.05
MACD -0.02 0.00
Stochastic Oscillator 65.48 72.73

Price Performance

Historical Comparison
MVIS
CGTX

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: